Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cerdulatinib |
Synonyms | |
Therapy Description |
Cerdulatinib (PRT062070) is an ATP-competitive inhibitor of JAK1/3 and SYK, which reduces downstream signaling and may result in decreased tumor growth (PMID: 25253883, PMID: 30333224). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cerdulatinib | PRT062070|PRT2070 | JAK1 Inhibitor - ATP competitive 5 JAK3 Inhibitor - ATP competitive 4 SYK Inhibitor 15 | Cerdulatinib (PRT062070) is an ATP-competitive inhibitor of JAK1/3 and SYK, which reduces downstream signaling and may result in decreased tumor growth (PMID: 25253883, PMID: 30333224). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |